ISTANBUL, Turkey, May 13 /PRNewswire/ --

- Japanese Pharmaceutical Company Establishes its own Turkish Subsidiary

- Important Step in Global Expansion

DAIICHI SANKYO, one of the world's leading research-driven pharmaceutical companies based in Japan, is establishing its own subsidiary in Turkey. The company, to be called DAIICHI SANKYO Ilaç Tikaret Ltd., will be headquartered in Istanbul and will initially focus on marketing the osteoporosis medication Evista (Raloxifen).

"Entering the Turkish market represents a major step in the expansion of our global presence," said Reinhard Bauer, CEO of DAIICHI SANKYO EUROPE. "With this decision, we are moving closer to achieving our goal of becoming one of Europe's leading pharmaceutical companies by 2015." Over the middle term, the company intends to significantly expand its line of medications, particularly with drugs coming from the company research pipeline to treat cardiovascular diseases. In addition, the company is interested in acquiring products and signing licensing agreements.

IMS Health, a leading international market-research institute in the pharmaceutical sector, expects Turkey to become one of the world's top ten pharmaceutical markets by 2010: "A multinational pharmaceutical group like DAIICHI SANKYO has to be located there," Bauer said.

The affiliate in Turkey will be strategically managed from Germany, where the European headquarters of the Japanese pharmaceutical company is located. The Munich office directs the company's affiliates in 10 other European countries where the company has had subsidiaries for a long period of time. These countries include major western European pharmaceutical markets like Germany, France, Great Britain, Spain and Italy.


DAIICHI SANKYO is a global pharmaceutical company that focuses exclusively on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of almost 5.5 billion EUR in fiscal year 2007, DAIICHI SANKYO is one of the world's leading pharmaceutical companies. The company's world headquarters is in Tokyo, and its European base is located in Munich. DAIICHI SANKYO has affiliates in 11 European countries and has been one of the strongest Japanese pharmaceutical companies located in Europe since it set up European production facilities and marketing offices in 1990. The company's research activities focus on the areas of cardiovascular diseases, hematology, diabetes, anti-infectives and cancer. Its aim is to develop medications that are "best" in their class or to create new classes of pharmaceutical drugs.

Forward-looking statements

This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO EUROPE GmbH. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO EUROPE GmbH assumes no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.

Dr. Thomas Portz Corporate Communications Phone +49-(0)-78-08-468 Olaf Lamberz Corporate Communications Phone +49-(0)-78-08-442

Dr. Thomas Portz, Corporate Communications, Phone +49-(0)-78-08-468, Olaf Lamberz, Corporate Communications, Phone +49-(0)-78-08-442,